Investment Rating - The report maintains a "Buy" rating for the food and beverage industry [2] Core Insights - The food and beverage industry experienced a decline of 2.33% from February 9 to February 13, 2026, underperforming the CSI 300 index by 2.69 percentage points [6][9] - The industry is currently at a historical low valuation, with a PE ratio of 21X, ranking 24th among Shenwan's primary industries [5][18] - High-end liquor sales showed strong performance during the Spring Festival, with leading brands like Moutai and Wuliangye experiencing significant growth, while mid-range products faced a decline of approximately 20% [6][7] Summary by Sections Industry Performance - From February 9 to February 13, 2026, the food and beverage sector's relative return was -2.5% over one month, -5.3% over three months, and -21.6% over twelve months [4] - The overall market indices showed positive movement, with the Shanghai Composite Index up by 0.41% and the Shenzhen Component Index up by 1.39% during the same period [9] Valuation Metrics - As of February 13, 2026, the food and beverage industry's PE ratio stands at 21X, with sub-sectors like other alcoholic beverages (52X), snacks (37X), and health products (34X) having higher valuations, while liquor (19X), beer (22X), and dairy (23X) are lower [5][18] Investment Recommendations - The report suggests focusing on three main investment lines: 1. Industry leaders with stable demand and strong risk resilience 2. Companies actively developing new products, channels, and consumption scenarios 3. Segments of the mass consumer goods industry that have shown growth potential and reasonable valuations after adjustments [7][44] - Specific companies to watch include Moutai, Shanxi Fenjiu, Anjuke Foods, Andeli, Yanjinpuzi, Babi Foods, Yanjing Beer, and Yili [7][44]

Industry Overview - The pharmaceutical and biotechnology sector increased by 0.14% this week, ranking 15th among 31 primary industries in the Shenwan index, outperforming the CSI 300 index by 1.47 percentage points, which fell by 1.33% [2] - The medical services sub-sector reported a rise of 1.31%, while traditional Chinese medicine and medical commercial sectors also saw increases of 2.56% and 0.57%, respectively [2] Company Performance - Top-performing companies in the medical services sector included Meidisi (+18.0%), Tongce Medical (+8.1%), and NuoSiGe (+5.7%), while underperformers included Haoyuan Pharmaceutical (-6.2%) and Baicheng Pharmaceutical (-4.5%) [3] - CXO-related companies experienced significant pullbacks [3] Valuation Metrics - The medical services sector's price-to-earnings (PE) ratio is currently at 34.43X, with a one-year maximum of 41.13X and a minimum of 28.46X; the price-to-book (PB) ratio stands at 3.49X, with a one-year maximum of 4.00X and a minimum of 2.48X [5] - The PE ratio increased by 0.56X and the PB ratio by 0.06X compared to the previous week [5] Regulatory Developments - The National Health Commission approved a pilot program for internet-based first consultations in Beijing, focusing on pediatric specialties, which marks a significant regulatory advancement for internet healthcare in major cities [6] - This initiative is expected to enhance online medical services and provide new market opportunities for private healthcare providers [6] Investment Recommendations - The report maintains a "buy" rating for the medical services industry, suggesting a focus on high-growth areas such as ADC CDMO and weight-loss drug supply chains, as well as companies with improving profit expectations like Aier Eye Hospital and Dean Diagnostics [7] - The report emphasizes the importance of a multi-tiered payment system and the resilience of medical demand in stabilizing the industry [7]

Group 1: ETF Market Overview - As of February 6, 2026, there are 1,439 ETFs in the Shanghai and Shenzhen markets, with a total asset management scale of 53,280.88 billion [2] - The breakdown includes 1,116 stock ETFs (31,401.67 billion), 53 bond ETFs (7,213.28 billion), 27 money market ETFs (1,615.16 billion), 17 commodity ETFs (3,225.87 billion), 211 cross-border ETFs (9,760.39 billion), and 15 unlisted ETFs (64.51 billion) [2] - In the week from February 2 to February 6, 2026, 10 new stock ETFs were listed, including two photovoltaic ETFs and eight others, with a total issuance scale of 36.04 billion [3] Group 2: ETF Performance Analysis - The median weekly return for stock ETFs was -1.63%, with the Sci-Tech Innovation Board New Energy ETF showing the highest increase of 4.09%, while the Gold Stock ETF had the largest decline of 13.25% [4] - The median weekly return for bond ETFs was 0.06%, with the 30-year Treasury ETF increasing by 0.93% and the convertible bond ETF decreasing by 0.30% [4] - The median weekly return for cross-border ETFs was -2.39%, with the Hang Seng Consumer ETF showing the highest increase of 4.81%, while the Brazil ETF had the largest decline of 11.63% [4] Group 3: PB-ROE Framework and Strategy - The PB-ROE framework categorizes industries into six quadrants, focusing on high PB high ROE industries and low PB medium ROE industries for investment opportunities [5] - Backtesting from 2017 to February 2024 shows that only the third and fifth quadrants achieved excess returns, with annualized excess returns of 4.27% and 1.55%, respectively [5] - A combined strategy from both quadrants resulted in an annualized return of 11.93% and an annualized excess return of 13.22% [6] Group 4: Investment Recommendations - The report recommends focusing on the industries of non-ferrous metals, transportation, and public utilities, with corresponding ETFs for each sector [8] - Additionally, it suggests monitoring non-ferrous metals ETF, chemical ETF, software ETF, food and beverage ETF, and photovoltaic 50 ETF for the upcoming week [8]

1. Report Industry Investment Rating - No relevant content provided. 2. Core Viewpoints - In 2025, the number and scale of existing public - funds increased, and the ETF market was much more popular. The new - issuance quantity and share of ETFs increased significantly, with annual growth rates of 114.79% and 119.10% respectively, far exceeding the 37.00% increase in the total number and - 0.69% change in the total share of public funds [2][17]. - In Q4 2025, stock - type, bond - type, and hybrid - type funds generally showed a decrease in stock positions and an increase in bond positions. Public funds shifted from Hong Kong stocks and the Science and Technology Innovation Board to the Growth Enterprise Market [3]. - In Q4 2025, the industries with a relatively large increase in the active position - adjustment ratio were non - banking finance, non - ferrous metals, and communications, while those with a relatively large decrease were electronics, media, and biomedicine. There was an obvious shift from growth and consumption styles to the cyclical style [4]. - Since 2025, the scale of FOF funds has increased against the trend, and the proportion of bond - type funds in the top - five heavy - position funds of FOF in the Q4 2025 report is relatively high [6]. 3. Summary by Directory 3.1 Public Fund Market Overview 3.1.1 Fund Market Composition and Issuance - As of the end of Q4 2025, there were 13,618 public funds in the market, with an increase of 1,259 this year. In terms of quantity, they were mainly composed of hybrid, bond, and stock - type funds, accounting for 35.33%, 29.32%, and 25.33% respectively. The total scale was 37.67 trillion yuan, an increase of 4.84 trillion yuan compared to the end of 2024, with a 12.85% increase in Q4 2025. In terms of scale, they were mainly composed of money - market, bond, and stock - type funds, accounting for 39.84%, 29.50%, and 16.06% respectively [14]. - From 2021 to 2025, the number and share of newly - issued public funds showed a downward trend, but they increased in 2025. In Q4 2025, 406 public funds were newly issued, with a total issuance share of 280.081 billion shares. In terms of quantity, stock - type funds accounted for 47.29%, and in terms of share, stock - type and bond - type funds accounted for 31.70% and 31.24% respectively [15]. - In 2025, the new - issuance volume and share of ETFs increased significantly. In Q4 2025, the quarterly growth rates of the cumulative number and share of ETFs were 5.81% and 12.17% respectively, exceeding the 2.38% and 3.15% growth rates of public funds. The annual growth rates of the new - issuance quantity and share of ETFs in 2025 were 114.79% and 119.10% respectively, far higher than those of public funds [17]. 3.1.2 Investor Structure - According to the semi - annual report of public funds in 2025, the proportion of institutional holders changed little compared to 2024. The increase in the proportion of institutional investors was mainly reflected in QDII funds and hybrid - type funds, while the proportion of institutional investors in bond - type and hybrid funds increased slightly. The proportion of individual investors increased mainly in alternative investment funds and FOF funds, and also increased in money - market funds [20]. - As of mid - 2025, the holding net values of institutional and individual investors were 16.51 trillion yuan and 17.71 trillion yuan respectively, accounting for 48.25% and 51.75%. Since H2 2017, the proportion held by individual investors has been slightly higher than that by institutional investors [23]. 3.2 Stock - type Funds 3.2.1 Q4 Position Changes - In Q4 2025, compared with Q3, stock - type, bond - type, and hybrid - type funds generally showed a decrease in stock positions and an increase in bond positions, while FOF funds increased their stock positions, mainly in stock - type FOF funds, with an increase of 1.83 pct [25]. - The stock positions of four types of active funds (partial - stock hybrid, flexible allocation, common stock, and balanced hybrid) decreased, and their positions in Hong Kong stocks also decreased, but their bond positions increased [27][28]. 3.2.2 Sector Allocation - In Q4 2025, public funds shifted from Hong Kong stocks and the Science and Technology Innovation Board to the Growth Enterprise Market. The allocation market value of the Growth Enterprise Market increased by 2.65%, and the allocation ratio increased by 1.98%, reaching 18.61% at the end of Q4, second only to the main board [37]. 3.2.3 Industry and Style Allocation - In Q4 2025, 16 Shenwan primary industries had an increase in the active position - adjustment ratio, and 15 had a decrease. The industries with a relatively large increase were non - banking finance, non - ferrous metals, and communications, while those with a relatively large decrease were electronics, media, and biomedicine [43]. - There was an obvious shift from growth and consumption styles to the cyclical style in Q4 2025. The cyclical style had the largest increase in market - value proportion after removing the passive increase caused by the increase in Q4, with an active position - adjustment ratio increase of 2.06% [48]. 3.2.4 Individual Stock Allocation - As of the end of Q4 2025, the top 3 stocks in terms of market value of shares held were Zhongji Innolight, Xinyisheng, and Contemporary Amperex Technology, and the top 3 in terms of the proportion of market value of shares held to the floating market value were BeiGene - U, Reagent Biotech, and Ninebot Inc. - WD [4][49]. - In Q4 2025, the top 3 stocks with active position - increases were Ping An Insurance (Group) Company of China, Shandong Precision, and Tianhua New Energy, and the top 3 with active position - decreases were Foxconn Industrial Internet, Alibaba Group Holding Limited, and Semiconductor Manufacturing International Corporation [4]. 3.3 Bond - type Funds - As of the end of Q4 2025, there were 3,993 bond - type funds, an increase of 57 compared to the previous quarter, with a total scale of 11.11 trillion yuan, an increase of 373.431 billion yuan compared to the previous quarter. The increase in the scale was mainly due to the increase in the scale of passive index - type bond funds and hybrid bond - type secondary funds [63]. - In Q4 2025, except for convertible bond - type funds and enhanced index - type bond funds, the durations of other types of bond - type funds changed little. The durations of mixed - level - 1 bonds, mixed - level - 2 bonds, medium - and long - term pure - bond funds, and partial - bond hybrid funds showed a downward trend in the second half of 2025 after reaching a historical high at the end of Q2 2025 [5]. 3.4 FOF Funds - Since 2025, the scale of FOF funds has increased against the trend. In Q4 2025, the total scale of FOF funds increased by 50.699 billion yuan, with a faster growth rate than in Q3. The top 3 FOF funds in terms of scale proportion were partial - bond hybrid, partial - stock hybrid, and target - date FOF funds, accounting for 60.92%, 14.50%, and 11.01% respectively [70]. - Among the 43 FOF funds issued in Q4 2025, 41 were hybrid - type FOF funds. E Fund Ruyi Ying'an 6 - month Holding A had the largest issuance share of 3.164 billion shares [71]. - According to the top - ten heavy - position funds of FOF funds in the Q4 2025 report, the top - five heavy - position funds were all bond - type funds, and most of the FOF heavy - position funds were bond - type funds, with Haifutong CSI Short - term Financing Bond ETF having the highest total holding market value of 5.976 billion yuan [76].

Industry and Company Overview - The medical consumables sector showed a slight increase, with the sector index closing at 6067.61 points, up by 0.35% [2] - The performance of leading companies in the medical consumables sector included Maipu Medical (+8.5%), Hualan Biological (+7.5%), and Zhend Medical (+6.7%), while underperformers included Microelectrophysiology (-2.9%) and Daobo Medical (-3%) [2] Market Valuation Metrics - As of February 6, the medical consumables sector had a PE ratio of 36.1X, down by 0.23X from the previous week, with a one-year high of 40.1X and a low of 28.88X; the PB ratio was 2.61X, with a one-year high of 2.92X and a low of 2.13X [4] Recent Developments - Microelectrophysiology's product, a disposable intracardiac ultrasound imaging catheter, has been approved for market release, enhancing its core product offerings in cardiac intervention and filling a gap in integrated ultrasound imaging and electrophysiological mapping solutions [5] Investment Recommendations - There is a high certainty of continued performance recovery for some high-value consumable companies, driven by recent approvals of innovative products and overseas business development, which are expected to create new growth points outside of centralized procurement [6] - The report suggests focusing on leading companies with strong cost control and innovation capabilities, particularly in the orthopedic implants, cardiovascular intervention devices, and neurosurgical implants sectors, as well as those with advantages in rehabilitation and chronic disease management [6][7]

Investment Rating - The industry investment rating is "Overweight" (maintained) [4] Core Insights - The medical consumables sector saw a slight increase of 0.35% last week, with the sector index closing at 6067.61 points [6] - The PE ratio for the medical consumables sector is 36.1X, which is a decrease of 0.23X from the previous week, with a one-year maximum of 40.1X and a minimum of 28.88X [7] - The recent approval of innovative high-value consumables is expected to drive performance recovery and growth in the sector [21] Summary by Sections Industry Performance - The medical consumables sector outperformed the CSI 300 index by 1.47 percentage points, ranking 15th among the Shenwan first-level industries [6][10] - Over the past 12 months, the absolute return for the sector was 15%, while the relative return was -4% compared to the CSI 300 [5] Valuation Metrics - As of February 6, the sector's PB ratio stands at 2.61X, with a one-year maximum of 2.92X and a minimum of 2.13X [7][18] Industry Dynamics and Key Announcements - A new product, a disposable intracardiac ultrasound imaging catheter, has been approved, which integrates ultrasound imaging with catheter positioning information, enhancing diagnostic capabilities in cardiac procedures [20] - The approval of innovative products and the development of overseas markets are anticipated to provide new growth points for companies in the sector [21] Investment Recommendations - The report suggests closely monitoring the performance of innovative high-value consumables companies, particularly those with strong product lines and innovation capabilities, such as Huatai Medical, Microelectrophysiology, and Maipu Medical [21][23] - It also highlights the importance of companies that can improve their performance margins, particularly in the orthopedic consumables sector, such as Weigao Orthopedics [21][23]

Investment Rating - The industry investment rating is maintained at "Overweight" [2][9]. Core Insights - The vaccine industry is experiencing a transition from scale expansion to innovation-driven growth, with short-term pain due to supply-demand imbalance and homogenized competition, but the long-term positive outlook remains unchanged [9][27]. - Recent advancements in vaccine technology and policy changes are expected to drive demand, particularly with the expansion of the immunization program for Japanese encephalitis vaccines in certain regions [4][9]. - Companies like Zhifei Biological are making significant progress with new vaccine candidates, including an mRNA vaccine for shingles and a lyophilized inactivated vaccine for chickenpox, which could enhance their competitive edge [4][9]. Summary by Sections Industry Performance - The vaccine sector has seen a cumulative decline of 11.36% since 2025, with a recent weekly drop of 1.42% [5][11]. - Relative performance against the CSI 300 index shows a decline of 29% over the past 12 months [4]. Company Developments - Zhifei Biological has received clinical trial approval for two new vaccines, indicating progress in both mRNA and inactivated vaccine technologies [4]. - The company is focusing on innovative vaccine development to enhance its product pipeline and market competitiveness [9]. Market Dynamics - The vaccine industry is currently facing challenges such as high competition among Me-too products and a decline in demand due to consumer hesitancy [8][24]. - The industry is expected to adjust its pipeline strategies, emphasizing innovation and multi-valent products to improve market positioning [8][24]. Valuation Metrics - The vaccine sector's price-to-earnings (PE) ratio is reported at 65.37X, with a recent decrease of 1.47X, while the price-to-book (PB) ratio stands at 1.21X [7][19]. - The PE ratio is at the 55.06% percentile since 2013, indicating a relatively high valuation compared to historical data [7]. Investment Recommendations - The report suggests focusing on companies with strong research and innovation capabilities, particularly those with differentiated product offerings, such as CanSino [9][27]. - Long-term investment opportunities are anticipated in the context of innovation and international market expansion [8][9].

Investment Rating - The industry rating is maintained at "Overweight" [7][36] Core Insights - The central bank's 2026 credit market work meeting emphasized the need for enhanced financial support in the consumer sector, with a focus on expanding domestic demand during the 14th Five-Year Plan period [6][32] - Structural monetary policy tools will be implemented to support key areas, including small and micro enterprises, technological innovation, and green upgrades [7][33] - Financial support for consumption is expected to increase, particularly in sectors such as health care, cultural tourism, and new consumption areas like digital and green initiatives [7][34] Summary by Sections Industry Performance - The banking sector index rose by 1.70% during the period from February 2 to February 8, 2026, outperforming the CSI 300 index by 3.04 percentage points [11] - The performance of various banking segments showed that city commercial banks led the market [11] Financial Market Conditions - The central bank's net withdrawal from the open market was 656 billion yuan, indicating a relatively loose funding environment [19] - The average issuance rates for interbank certificates of deposit increased, with net financing amounting to 236.19 billion yuan in February [22][23] Investment Recommendations - With the collaboration of financial and fiscal policies, the "opening red" phase of credit issuance is expected to remain stable, which may enhance core revenue growth for banks [9][36] - High dividend yields in bank stocks present significant investment value, with recommendations for state-owned banks and flexible regional banks [9][36]

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [7]. Core Views - The recent policy from the National Healthcare Security Administration aims to transform the role of healthcare insurance from a payer to an innovator, significantly impacting the IVD industry by promoting solutions that integrate "testing + AI + services" [5][51]. - The domestic IVD industry is currently in a bottoming phase, with a strong focus on the growth potential of immunodiagnostics, particularly in chemiluminescence and molecular diagnostics such as PCR [5][51]. - The report highlights that the biochemical diagnostics sector in China has largely completed its localization process, reducing reliance on foreign technologies [5]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 0.14%, ranking 15th among 31 primary industries, while the IVD sector fell by 1.28% [2][10]. - The IVD sector's current PE (ttm) is 39.37X, with a PB (lf) of 1.80X, showing a slight decrease from the previous week [4][31]. Company Performance - Notable performers in the medical services sector include SAIKOSHI (+14.5%), Ruiang Gene (+3.1%), and Rendu Bio (+2.6%), while underperformers include Cap Bio (-6.8%) and Hotgen Bio (-6.4%) [3][26]. - The report suggests focusing on companies like YHLO Biotech and Shengxiang Bio in the immunodiagnostics and molecular diagnostics fields due to their growth potential [5][51]. Market Trends - The report indicates that the IVD industry is experiencing a shift towards integrating new technologies and payment methods, driven by recent policy changes [5][51]. - The overall IVD market is expected to continue its steady growth, with significant opportunities arising from the integration of AI and innovative products [5][51].

Investment Rating - The report maintains a "Buy" rating for the mechanical industry [6] Core Insights - The mechanical sector outperformed the market, with significant increases in engineering machinery and photovoltaic equipment [3][12] - January sales of earth-moving machinery exceeded expectations, with excavator sales reaching 18,708 units, a year-on-year increase of 49.5% [4] - The merger of SpaceX and xAI is expected to accelerate the development of space photovoltaic applications, benefiting domestic photovoltaic equipment manufacturers [5][7] - The upcoming launch of Tesla's Optimus V3 humanoid robot is anticipated to drive demand for core components in the robotics sector [8] Market Performance - The mechanical industry index rose by 0.4% in the past week, while the Shanghai Composite Index fell by 1.3% [3][12] - Year-to-date, the mechanical industry has increased by 6.7%, with photovoltaic processing equipment leading at a 50.4% increase [13] Segment Summaries Engineering Machinery - January sales of excavators and loaders were the highest for the same period since 2021, driven by high commodity prices and increasing demand from emerging markets [4] - The report suggests that domestic and international demand will continue to resonate, leading to accelerated performance recovery for major manufacturers [9] Photovoltaic Processing Equipment - Tesla's expansion in solar manufacturing and the merger of SpaceX and xAI are expected to significantly boost orders for domestic photovoltaic equipment manufacturers [5][7] - The report highlights the potential for performance recovery in the photovoltaic processing equipment sector [9] Robotics - The anticipated production of Tesla's Optimus V3 humanoid robot is expected to significantly increase demand for key components in the robotics supply chain [8][10] - The report emphasizes the growth potential in the humanoid robotics sector, driven by increased investment and production capabilities [10]